Abiopharma

🔍 Mazzucchelli Silvia (Executive)

Company: VTEX (NYSE: VTEX)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 971 shares of Class A Common Shares (Direct)
  Date: 2026-04-01 | Code: C | equity_swap_involved: false | shares_owned_after: 8,908.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,057 shares of Class A Common Shares (Direct)
  Date: 2026-04-01 | Code: C | equity_swap_involved: false | shares_owned_after: 9,965.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 971 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: C | equity_swap_involved: false | shares_owned_after: 4,858.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F2
• Sold 1,057 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: C | equity_swap_involved: false | shares_owned_after: 9,520.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3

Footnotes:

• F1: Each Restricted Stock Unit ("RSUs") represents a contingent right to receive shares of Issuer Class A common stock on a one-for-one basis.
• F2: Represents RSUs. 8.33% of which vested on October 1, 2024, and the remaining amount of which vests in tranches of 8.33% every three (3) months thereafter
• F3: Represents RSUs. 8.33% of which vested on October 1, 2025, and the remaining amount of which vests in tranches of 8.33% every three (3) months thereafter
• REMARKS: Due to the Issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the Issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.